What's new? Log in Free sign up

Surface Oncology (SURF) News and press releases

Company Profile

News

From Benzinga Pro

Wedbush Reiterates Outperform on Surface Oncology, Maintains $3 Price Target

News, Price Target, Reiteration, Analyst Ratings

Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on Surface Oncology, Maintains $6 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Surface Oncology (NASDAQ:SURF) with a Buy and maintains $6 price target.

12 Health Care Stocks Moving In Thursday's After-Market Session

Vaccinex Announces First Patient Dosed With Anti-CCR8 Antibody Licensed To Surface Oncology

Biotech, News, FDA, General

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that its

Surface Oncology Announces First Patient Dosed In A Phase 1/2 Study Evaluating SRF114, A Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Biotech, News, FDA, General

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the first patient has been dosed in its

Press releases

From Benzinga Pro

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022

Earnings, Press Releases

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

News, Press Releases

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

Non-small Cell Lung Cancer Clinical Trial 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight

News, Press Releases

"Non-small Cell Lung Cancer Pipeline"Non-small Cell Lung Cancer (NSCLC) pipeline constitutes 135+ key companies continuously working towards developing 150+ NSCLC treatment therapies, analyzes

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Health Care, Press Releases

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.